Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.

doi:10.1002/ijc.70019

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical impact of real-time androgen receptor alteration monitoring on metastatic castration-resistant prostate cancer treatment in real-world settings.

International journal of cancer - 15 Nov 2025

Stitz Regina, Stoiber Franz, Silye Renè, Rebhan Elisabeth, Dunzinger Michael, Pühringer Franz, Heitzer Ellen, Hauser-Kronberger Cornelia

Abstract excerpt

Androgen receptor (AR) alterations contribute to resistance against androgen receptor signaling inhibitors (ARSi) in metastatic castration-resistant prostate cancer (mCRPC). This study evaluated AR alteration monitoring via liquid biopsy in routine clinical practice. To this end, we enrolled 39 mCRPC patients in a real-world clinical setting and monitored disease progression with progression-free survival (PFS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Androgen Receptor Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Kaplan-Meier Estimate

Share to Liquid Biopsy

Share to Progression-Free Survival

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 40558023
DOI: 10.1002/ijc.70019
PMCID: PMC12439075

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.